¹**Utility of TaqMan Array Cards for detection of Acute febrile illness etiologies in patients** ²**suspected of Viral Hemorrhagic Fever Infections in Uganda**

Authors: Akurut GG^{1,4}, Nyakarahuka L^{2,4}, Whitmer S³, Namanya D², Kilama K¹, Mulei S²,
Angkalang Tanggal ng Pandang Pan

4 Baluku J², Tumusime A², Kyondo J², Julius J Lutwama, Trevor Shoemaker, Patel K³, Joel 5 Montgomery, Klena JD³, Balinandi S²

⁶**Corresponding Author**

⁷Gloria Grace Akurut; akurutgloria @gmail.com

⁸**Institutional affiliation**

9 Uganda Wildlife Authority¹, Uganda Virus Research Institute², Centers for Disease Control and

10 Prevention³, College of Veterinary Medicine Animal Resources and Biosecurity, Makerere
11 University⁴

University⁴

¹²**Abstract**

13 **Introduction:** Attributing a causative agent to acute febrile illnesses (AFI) remains a challenging diagnostic task for clinical and public health laboratories. The need for developing, validating 14 diagnostic task for clinical and public health laboratories. The need for developing, validating
15 and implementing a multi-pathogen diagnostic assay able to detect a wide range of AFI-15 and implementing a multi-pathogen diagnostic assay able to detect a wide range of AFI-
16 associated pathogens should be prioritized in low-resource settings. The use of the previously 16 associated pathogens should be prioritized in low-resource settings. The use of the previously
17 developed Acute Febrile Illness TagMan Array card (AFI-TAC), which detects 26 pathogens in 17 developed Acute Febrile Illness TaqMan Array card (AFI-TAC), which detects 26 pathogens in
18 less than 2 hours post-sample nucleic acid extraction, was selected for evaluation in Uganda. less than 2 hours post-sample nucleic acid extraction, was selected for evaluation in Uganda.

19 **Methods:** This was a cross-sectional retrospective study in which archived viral hemorrhagic
20 fever (VHF)-negative blood and plasma samples were selected. Samples were previously tested 20 fever (VHF)-negative blood and plasma samples were selected. Samples were previously tested
21 and archived at the Uganda Virus Research Institute (UVRI)-Viral Hemorrhagic Fever (UVRI-21 and archived at the Uganda Virus Research Institute (UVRI)-Viral Hemorrhagic Fever (UVRI-
22 VHF) Laboratory from August 2018 to March 2019 as part of the routine surveillance program. 22 VHF) Laboratory from August 2018 to March 2019 as part of the routine surveillance program.
23 The VHF case definition included, temperature of >38.0 °C, additionally with bleeding and any 23 The VHF case definition included, temperature of \geq 38.0 °C, additionally with bleeding and any other febrile symptoms. Samples were then tested using an AFI-TAC for 35 potential pathogen 24 other febrile symptoms. Samples were then tested using an AFI-TAC for 35 potential pathogen
25 targets. Selected positive samples were subsequently assessed using a second, pathogen-specific 25 targets. Selected positive samples were subsequently assessed using a second, pathogen-specific
26 simplex PCR assay. Epidemiological data were linked to the laboratory findings to assess for risk 26 simplex PCR assay. Epidemiological data were linked to the laboratory findings to assess for risk
27 factors for infection. factors for infection.

Results: A total of 82 samples were selected for this study, of which 152 (83.52%) were from
29 Uganda, 22 (12.09%) from the Democratic Republic of the Congo, 7 (3.85 %) from South 29 Uganda, 22 (12.09%) from the Democratic Republic of the Congo, 7 (3.85 %) from South
30 Sudan, and 1 (0.55%) from Kenya. The median age of the patients was 27 years, with 145 30 Sudan, and 1 (0.55%) from Kenya. The median age of the patients was 27 years, with 145
31 (79.67%) samples from adults >18 years. Seven pathogens were detected with the most prevalent 31 (79.67%) samples from adults >18 years. Seven pathogens were detected with the most prevalent
32 being *Plasmodium* spp. 26.92% (49/182) of which 69.4% (34/49) were *Plasmodium falciparum*, 32 being *Plasmodium* spp. 26.92% (49/182) of which 69.4% (34/49) were *Plasmodium falciparum*,
33 *Yellow fever virus* 2 (1.10 %), non-typhoidal *Salmonella* 3 (1.65%), *Salmonella enterica serovar* ³³*Yellow fever* virus 2 (1.10 %), non-typhoidal *Salmonella* 3 (1.65%), *Salmonella enterica serovar* ³⁴Typhi (1.10%), *Leptospira* spp. 1 (0.54%), *Streptococcus pneumonia* (0.55%), and *Rickettsia* 35 spp. (0.55%). Epidemiological correlation revealed a significant relationship between case
 36 fatality (p=0.002) and disease while age, occupation, sex and disease were not significant.

fatality $(p=0.002)$ and disease while age, occupation, sex and disease were not significant.

37 Cough was found to be the only clinical symptom associated with being infected with $Plasmodium$ (p=0.016). ³⁸*Plasmodium* (p=0.016).

39 **Conclusion**: The use of TAC is feasible, readily adoptable diagnostic assay for use in Uganda
40 and will be useful when incorporated into the national testing algorithm for the differential 40 and will be useful when incorporated into the national testing algorithm for the differential
41 diagnosis of AFI during an outbreak and surveillance.

diagnosis of AFI during an outbreak and surveillance.

⁴²**Key words**

⁴³Taqman array card, viral hemorrhagic fever, acute febrile illness, etiologies

⁴⁴**Background** 45 Viral hemorrhagic fevers (VHF) are acute febrile illnesses (AFI) characterized by fever with
46 body temperatures $\geq 37.5^{\circ}$ C which may persist for longer than 72 hours. Other symptoms 46 body temperatures $\geq 37.5^{\circ}$ C which may persist for longer than 72 hours. Other symptoms
47 commonly associated with AFI include headache, cough, vomiting, diarrhea, fatigue, and 47 commonly associated with AFI include headache, cough, vomiting, diarrhea, fatigue, and
48 convulsions. Establishing a causative agent based solely on clinical presentation remains a 48 convulsions. Establishing a causative agent based solely on clinical presentation remains a
49 challenge due to the non-specific clinical presentation of AFI, making it difficult to infer a 49 challenge due to the non-specific clinical presentation of AFI, making it difficult to infer a
50 particular symptom to a specific disease. And without laboratory diagnostic testing, treatment is 50 particular symptom to a specific disease. And without laboratory diagnostic testing, treatment is
51 often delayed or ineffective (Maze *et al.*, 2018). This is especially important in countries that 51 often delayed or ineffective (Maze *et al.*, 2018). This is especially important in countries that
52 have experienced multiple, and often simultaneous outbreaks of diseases caused by VHFs such 52 have experienced multiple, and often simultaneous outbreaks of diseases caused by VHFs such
53 as filoviruses. Rift Valley Fever virus (RVFV), and /or Crimean Congo Hemorrhagic Fever virus 53 as filoviruses, Rift Valley Fever virus (RVFV), and /or Crimean Congo Hemorrhagic Fever virus
54 (CCHFV) that are capable of spreading rapidly through human and animal populations. Yet. 54 (CCHFV) that are capable of spreading rapidly through human and animal populations. Yet,
55 these pathogens are of significant public health concern and their detection and control is these pathogens are of significant public health concern and their detection and control is
56 important for global health security and socio-economic stability (Balinandi et al., 2024, 56 important for global health security and socio-economic stability(Balinandi *et al.*, 2024, 57 Shoemaker *et al.*, 2013). In Uganda, because malaria caused by *Plasmodium falciparum* is a 57 Shoemaker *et al.*, 2013). In Uganda, because malaria caused by *Plasmodium falciparum* is a major cause of AFI, many patients with fever are placed on antimalarial prophylaxis in the 58 major cause of AFI, many patients with fever are placed on antimalarial prophylaxis in the absence of laboratory diagnostic testing (Ghai *et al.*, 2016) which has resulted in several cases of 59 absence of laboratory diagnostic testing (Ghai *et al.*, 2016) which has resulted in several cases of antimalarial resistance (Agaba *et al.*, 2024), or generally what is called Antimicrobial resistance 60 antimalarial resistance (Agaba *et al.*, 2024), or generally what is called Antimicrobial resistance
61 (Mambula *et al.*, 2023)in Uganda. Moreover, the approach of symptomatic treatment in 61 (Mambula *et al.*, 2023)in Uganda. Moreover, the approach of symptomatic treatment in hospitals has been associated with the under-diagnosis of other AFIs known to exist in Uganda 62 hospitals has been associated with the under-diagnosis of other AFIs known to exist in Uganda
63 that include brucellosis, leptospirosis, rickettsia, chikungunya, Dengue fever and orthopoxyirus 63 that include brucellosis, leptospirosis, rickettsia, chikungunya, Dengue fever and orthopoxvirus
64 infection (Kharod *et al.*, 2016), as has been revealed in the recently implemented Mortuary 64 infection (Kharod *et al.*, 2016), as has been revealed in the recently implemented Mortuary
65 Surveillance Program (manuscript in preparation). Surveillance Program (manuscript in preparation).

66 Diagnosis of a VHF is highly dependent on the direct detection of the causative virus by culture
67 or the presence of viral nucleic acids in the sample from a suspect case. Although the humoral 67 or the presence of viral nucleic acids in the sample from a suspect case. Although the humoral immune response can be utilized, (Racsa *et al.*, 2016) it is not practically used for diagnosis. 68 immune response can be utilized, (Racsa *et al.*, 2016) it is not practically used for diagnosis.
69 Traditional methods of clinical microbiology such as isolation which requires BSL-4 lab and 69 Traditional methods of clinical microbiology such as isolation which requires BSL-4 lab and
60 convalescent-phase serology are slow and cumbersome, and values from common laboratory 70 convalescent-phase serology are slow and cumbersome, and values from common laboratory
71 parameters like urinalysis, chemistries, and hematology are not unique, although they may guide 71 parameters like urinalysis, chemistries, and hematology are not unique, although they may guide
72 patient identification. Molecular diagnosis of infectious diseases using nucleic acid amplification 72 patient identification. Molecular diagnosis of infectious diseases using nucleic acid amplification
73 techniques (NAAT) such as the polymerase chain reaction (PCR) can be designed to be highly 73 techniques (NAAT) such as the polymerase chain reaction (PCR) can be designed to be highly
74 sensitive and specific to detect infectious agents. To increase the efficiency of detection. NAAT

75 methods are being designed to target more than one infectious agent in an assay; however,
76 multiplex methods are often less sensitive compared to the singleplex (Haiia, 2017). Tagman 76 multiplex methods are often less sensitive compared to the singleplex (Hajia, 2017). Taqman
77 Array Cards (TAC) are microfluidic test cards designed to perform multiple real-time PCR 77 Array Cards (TAC) are microfluidic test cards designed to perform multiple real-time PCR
78 specific for several different pathogens (depending on the TAC configuration) using primers and 78 specific for several different pathogens (depending on the TAC configuration) using primers and
79 probes preloaded in to the microwells of a 384 well plate. Between 1-8 samples can be tested in 79 probes preloaded in to the microwells of a 384 well plate. Between 1-8 samples can be tested in
80 parallel against 12 to 384 assay targets in as little as 10fg of DNA isolated from pure bacterial 80 parallel against 12 to 384 assay targets in as little as 10fg of DNA isolated from pure bacterial
81 cultures (Rose *et al.*, 2012) using TAC. At the current estimates, the cost of using the TAC is 81 cultures (Rose *et al.*, 2012) using TAC. At the current estimates, the cost of using the TAC is
82 ~80 USD per sample. When analytical validation using clinical specimens was compared 82 ~80 USD per sample. When analytical validation using clinical specimens was compared
83 between AFI TAC performance and individual PCR assavs, an 88% sensitivity and 99% 83 between AFI TAC performance and individual PCR assays, an 88% sensitivity and 99% specificity was observed (Liu *et al.*, 2016). Thus, the multi-pathogen detection card is convenient 84 specificity was observed (Liu *et al.*, 2016). Thus, the multi-pathogen detection card is convenient
85 for screening AFIs during outbreaks or routine surveillance, consequently reducing the time 85 for screening AFIs during outbreaks or routine surveillance, consequently reducing the time
86 taken to ascertain the cause of illness, and therefore prophylaxis. Whereas NGS provides the 86 taken to ascertain the cause of illness, and therefore prophylaxis. Whereas NGS provides the technical solution for pathogen detection efficiency, conclusive results usually take long to be 87 technical solution for pathogen detection efficiency, conclusive results usually take long to be obtained and it is expensive (Lesho *et al.*, 2016). The TAC is designed to avoid amplicon 88 obtained and it is expensive (Lesho *et al.*, 2016). The TAC is designed to avoid amplicon contamination with improved detection efficiency for multiple pathogens. contamination with improved detection efficiency for multiple pathogens.

90 In Uganda, routine VHF surveillance is conducted year-round at the Uganda Virus Research
91 Institute (UVRI). The majority of samples submitted from symptomatic patients test negative for 91 Institute (UVRI). The majority of samples submitted from symptomatic patients test negative for
92 a VHF, vet due to their acute and fulminant nature of illness, there is a need to identify the 92 a VHF, yet due to their acute and fulminant nature of illness, there is a need to identify the causative etiologies these patients suffer from (Balinandi *et al.*, 2024). A multi-pathogen 93 causative etiologies these patients suffer from (Balinandi *et al.*, 2024). A multi-pathogen detection assay for differential diagnosis of acute febrile illnesses reduces the time taken to 94 detection assay for differential diagnosis of acute febrile illnesses reduces the time taken to
95 detect numerous etiologies which can lead to timely public health interventions. This study 95 detect numerous etiologies which can lead to timely public health interventions. This study
96 utilized the TAC assay to detect alternative etiologies for illnesses in patients whose samples 96 utilized the TAC assay to detect alternative etiologies for illnesses in patients whose samples
97 tested negative for VHFs. tested negative for VHFs.

⁹⁸**Materials and methods**

⁹⁹*Study design and population*

100 This cross-sectional retrospective study utilized 182 archived samples submitted to the VHF
101 laboratory at UVRI from August 2018 to March 2019 as part of the National VHF surveillance 101 laboratory at UVRI from August 2018 to March 2019 as part of the National VHF surveillance
102 program testing. The study was given approval by the Director General of the Ministry of 102 program testing. The study was given approval by the Director General of the Ministry of Health, Republic of Uganda. Health, Republic of Uganda.

¹⁰⁴*Inclusion and exclusion criteria*

105 Patients presenting with high fever, with or without hemorrhagic signs, and that tested negative
106 by real-time PCR using primers specific for VHF viruses including Marburg virus, Ebola viruses 106 by real-time PCR using primers specific for VHF viruses including Marburg virus, Ebola viruses
107 (Sudan, Bundibugyo and Zaire), Crimean Congo Hemorrhagic Fever virus (CCHF) and Rift 107 (Sudan, Bundibugyo and Zaire), Crimean Congo Hemorrhagic Fever virus (CCHF) and Rift
108 Valley Fever virus (RVF), were included in this study. Six known positive samples (RVFV= 5 108 Valley Fever virus (RVF), were included in this study. Six known positive samples (RVFV= 5 and CCFV= 1) were used to verify the TAC assay characteristics. VHF surveillance samples 109 and CCFV= 1) were used to verify the TAC assay characteristics. VHF surveillance samples collected between August 2018 and March 2019 were included in this study. collected between August 2018 and March 2019 were included in this study.

¹¹¹*Sample acquisition and nucleic acid extraction*

112 Study samples were retrieved from storage freezers and thawed at 4°C overnight. All downstream procedures for RNA extraction used the MagMax RNA isolation kit (ThermoFisher 113 downstream procedures for RNA extraction used the MagMax RNA isolation kit (ThermoFisher scientific, Carlifornia, USA), according to the manufacturer's instructions. Briefly, from each 114 scientific, Carlifornia, USA), according to the manufacturer's instructions. Briefly, from each
115 sample, 100 µl was removed for RNA extraction using an automated Magmax 15 well bead-115 sample, 100 µl was removed for RNA extraction using an automated Magmax 15 well bead-
116 based extractor (Applied Biosystems, ThermoFisher scientific, Carlifornia, USA,). Samples were 116 based extractor (Applied Biosystems, ThermoFisher scientific, Carlifornia, USA,). Samples were
117 inactivated in a high containment laboratory (HCL) by adding 100 µl of patient blood or 117 inactivated in a high containment laboratory (HCL) by adding 100 μ l of patient blood or nuclease free water (negative control) to 400 μ l of lysis buffer to which 2 μ l of carrier RNA had 118 nuclease free water (negative control) to 400 μ l of lysis buffer to which 2 μ l of carrier RNA had
119 been added. This was followed by 10 minutes of incubation before transfer of inactivated 119 been added. This was followed by 10 minutes of incubation before transfer of inactivated
120 samples into sterile cryogenic vials and removal from the HCL to a BSL-2 low-containment 120 samples into sterile cryogenic vials and removal from the HCL to a BSL-2 low-containment
121 laboratory for nucleic acid extraction. Inactivated samples were extracted according to the 121 laboratory for nucleic acid extraction. Inactivated samples were extracted according to the manufacturer's instructions and eluted in 90ul of elution buffer. The eluates were transferred to 122 manufacturer's instructions and eluted in 90 μ l of elution buffer. The eluates were transferred to sterile labelled tubes and stored at \Box 20 °C or kept at 4 °C for immediate analysis. 123 sterile labelled tubes and stored at \Box 20 °C or kept at 4 °C for immediate analysis.

¹²⁴*Taqman Array Card preparation and analysis*

125 Taqman Array cards first described by (Liu *et al.*, 2016), detecting 26 AFI associated etiologies were used. Each TAC tested a total of six patient samples, a positive and a negative control. 126 were used. Each TAC tested a total of six patient samples, a positive and a negative control.
127 Mastermix was prepared to include 1x Ag-Path-ID 2X rt PCR buffer and the enzyme mix 127 Mastermix was prepared to include 1x Ag-Path-ID 2X rt PCR buffer and the enzyme mix
128 (Applied Biosystems ThermoFisher scientific, Carlifornia, USA). Into each microfuge tube, 80 128 (Applied Biosystems ThermoFisher scientific, Carlifornia, USA). Into each microfuge tube, 80 μ l of the prepared master mix and 20 μ l of the RNA were added. This was followed by brief 129 μ l of the prepared master mix and 20 μ l of the RNA were added. This was followed by brief vortexing to mix them and then a short spin. vortexing to mix them and then a short spin.

131 TAC cards were equilibrated to ambient temperature in their original packages prior to use. 100
132 ul of each sample mix was added into the inlet port of each channel, the card centrifuged at que 132 per queste of each sample mix was added into the inlet port of each channel, the card centrifuged at 133 1,200 rpm for 2 min, the ports sealed and removed following the manufacturer's instructions. 1,200 rpm for 2 min, the ports sealed and removed following the manufacturer's instructions.
134 Amplification was performed on a VIIA7 real-time PCR system (Life Technologies) using the 134 Amplification was performed on a VIIA7 real-time PCR system (Life Technologies) using the cycling conditions as follows 20 min 45 $^{\circ}$ C, 10 min 95 $^{\circ}$ C, followed by 40 cycles of 15 sec 95 135 cycling conditions as follows 20 min 45 °C, 10 min 95 °C, followed by 40 cycles of 15 sec 95
136 °C, 1 min 60 °C. Samples with a cycle threshold (Ct) fluorescent signal of \leq 35 were considered 136 °C, 1 min 60 °C. Samples with a cycle threshold (Ct) fluorescent signal of ≤35 were considered positive for the detected agent.

positive for the detected agent.

138 The data was organized in excel and analyzed in R-studio (MA, 139 Boston, USA). Univariate analysis was done to determine demographic characteristics and the 140 for means of linear communes and the different demographic characteristics A concentrated 140 frequency of disease occurrence among the different demographic characteristics. A generalized
141 linear model (glm) was developed to determine the general influence of occupation, age and 141 linear model (glm) was developed to determine the general influence of occupation, age and general influence of occupation, and F-142 gender on the acquisition of a disease; this was done to attain estimates (odds ratios), and F-
143 statistics all measured at a 95% level of significance. Logistic regression modelling was done to 143 statistics all measured at a 95% level of significance. Logistic regression modelling was done to
144 determine the relationship between clinical symptoms and *Plasmodium* infections and the model 144 determine the relationship between clinical symptoms and *Plasmodium* infections and the model
145 was validated using the Akaike information criterion (AIC) value. was validated using the Akaike information criterion (AIC) value.

¹⁴⁶**Results**

¹⁴⁷*Socio-demographic characteristics of study participants*

- 148 A total of 182 samples collected from August 2018 to March 2019 met the inclusion criteria. Of
149 the 182 samples, 64.29% were from males, the median age of the patients was 27 years (range 0-
- 149 the 182 samples, 64.29% were from males, the median age of the patients was 27 years (range 0-
150 80 years) and 79.67% were adults. The geographical distribution of samples selected under this
- 150 80 years) and 79.67% were adults. The geographical distribution of samples selected under this study was as follows; Uganda ($n=149$; 81.7%)), Democratic Republic of Congo ($n=21$; 11.8%),
- 151 study was as follows; Uganda (n=149; 81.7%)), Democratic Republic of Congo (n= 21; 11.8%), South Sudan (n=7; 3.76%), Kenya (n=1; 0.54%), and n=2; (2.15%) having no country of
- 152 South Sudan (n=7; 3.76%), Kenya (n=1; 0.54%), and n=2; (2.15%) having no country of residence recorded on the case report form. From Uganda, the regions were divided into three,
- 153 residence recorded on the case report form. From Uganda, the regions were divided into three,
154 West (n=106; 1%), Central (n=27; 18%) and North (n=16; 11%), (refer to Table 1).
- West (n=106; 1%), Central (n=27; 18%) and North (n=16; 11%), (refer to Table 1).

¹⁵⁵*Pathogens detected by TAC*

156 TAC detected 7 pathogens targets in (32%) samples (Table 1). The major etiologies detected
157 were *Plasmodium* spp., 26.9% (49/182), particularly 69% (34/49) were determined to be 157 were *Plasmodium* spp., 26.9% (49/182), particularly 69% (34/49) were determined to be 158 *Plasmodium falciparum* species. Other etiologies detected include: *Salmonella* spp. (n=3; 158 *Plasmodium falciparum* species. Other etiologies detected include; *Salmonella* spp. (n=3;
159 1.65%), while Yellow Fever virus (n=2; 1.1%) and *S.typhi* (n=2; 1.1%) were both detected in 159 1.65%), while Yellow Fever virus (n=2; 1.1%) and *S.typhi* (n=2; 1.1%) were both detected in
160 two samples. *Streptococcus pneumonia*, *Leptospira* and *Rickettsia* (0.55%) were each detected 160 two samples. *Streptococcus pneumonia*, *Leptospira* and *Rickettsia* (0.55%) were each detected in a single sample. in a single sample.

162 There was a statistical significance between case fatality and having disease (P value = 0.002
163 95% CI). That Case fatality rate of Leptospirosis. Rickettsia. Salmonella Typhi. Yellow fever and ¹⁶³95% CI). That Case fatality rate of Leptospirosis, Rickettsia, *Salmonella* Typhi, *Yellow fever* and 164 S. *pneumoniae* was 100%, while it was 16% and 33% for plasmodium and salmonella infections,
165 respectively (Table 2). Samples previously positive for individual real-time PCR (IRTP) RVF 165 respectively (Table 2). Samples previously positive for individual real-time PCR (IRTP) RVF $(n=5)$ and CCHF $(n=1)$ were included for assay verification and there was 100% agreement as 166 $(n=5)$ and CCHF $(n=1)$ were included for assay verification and there was 100% agreement as they also tested positive by TAC. The samples that tested positive for Yellow Fever virus by 167 they also tested positive by TAC. The samples that tested positive for Yellow Fever virus by TAC were found positive by individual real time PCR. There was no statistical significance at 168 TAC were found positive by individual real time PCR. There was no statistical significance at 169 95% confidence that any of the clinical characteristics presented were associated with 169 95% confidence that any of the clinical characteristics presented were associated with
170 Plasmodium infection besides cough (p value = 0.01695% CI) (refer to Table 3). Plasmodium infection besides cough (p value $= 0.016$ 95% CI) (refer to Table 3).

¹⁷¹**Table 1: Univariate analysis of disease outcome and socio-demographic parameters and** ¹⁷²**regions within Uganda**

173

¹⁷⁴**Table 2: Percentage frequency of diseased individuals among different demographic** parameters.

¹⁷⁶*Disease among categories; sex, age, occupation, status and region presented in percentages.*

¹⁷⁷*Status; dead or alive is more associated with having the disease (statistically significant).Lpt;*

¹⁷⁸*Leptospira, Pl; Plasmodium, Rk; Rickettsia, Sl; Salmonella, S.p; Streptococcus pneumonia, S.t;*

¹⁷⁹*Salmonella typhi, YF; Yellow fever*

¹⁸⁰**Table 3: Association between clinical characteristics including abdominal pain, chest pain,**

¹⁸¹**muscle pain, headache, cough, sore throat, conjunctivitis and skin rash and presence of**

¹⁸²**Plasmodium infections., cough is the only statistically significant clinical characteristic**

¹⁸⁵**DISCUSSION**

186 Multiplex pathogen detection tools like TAC PCR can be valuable tools for diagnosing multiple 187 infections for infectious disease surveillance (Rose *et al.*, 2012, Hercik *et al.*, 2017). Because 188 these systems are open, they can be custom-designed to investigate possible causes of syndromic 189 disease (e.g. acute febrile illness) or for priority diseases within a country or region and 190 environmental samples testing (Kodani *et al.*, 2011).

192 Prior to this study, after completion of the VHF testing algorithm (using simplex assays for ¹⁹³Ebolavirus, Sudan Ebolavirus, Bundibugyo Ebolavirus, Marburg virus, Crimean-Congo 194 Hemorrhagic fever virus and Rift Valley fever virus) at UVRI, no further testing would be 195 performed on a sample. In this study, of the 182 VHF-negative samples tested by TAC, at least 196 one organism was identified in 59 (32.4%) of the samples by AFI-TAC assay, practically 197 meaning that a diagnosis of the infectious cause of disease can be made for 1 of every 3 VHF-

¹⁹⁸negative cases. The most prevalent pathogen was *Plasmodium* spp. interestingly, the two cases of 199 yellow fever virus cases detected by this study triggered an outbreak investigation of this 200 etiology in Masaka district, Central Uganda, by the Ministry of Health and was confirmed by 201 singleplex PCR (https://www.health.go.ug/programs/uganda-national-expanded-program-on-202 immunisation-unepi/). From this study, Yellow fever virus disease severity and mortality was
203 associated with occupations such as hunting and farming which activities predispose people to ²⁰³associated with occupations such as hunting and farming which activities predispose people to 204 mosquito bites. Furthermore, Yellow fever cases were males similar to the outbreak in northern ²⁰⁵Uganda that found males were more likely than females to acquire the *Yellow fever* virus. This 206 predisposition of males towards YF infection was linked to economic activities undertaken by ²⁰⁷males around forests (Wamala *et al*., 2012).

²⁰⁹Similarly, both non-typhoidal and typhoidal *Salmonella enterica* were detected with non-typhus 210 salmonella (n=3, 1.65%), *Salmonella typhi* (n=2; 1.10%), as well as Leptospira (n=1; 0.54%), 211 and Rickettsia (0.55%). Finally, a single case of *Streptococcus pneumoniae*, was found. A
212 similar study from Tanzania found *Plasmodium* spp. to be the most common pathogen detected similar study from Tanzania found *Plasmodium* spp. to be the most common pathogen detected ²¹³(using the identical AFI card while *Leptospira* was only 3% of cases and *Salmonella enterica* ²¹⁴and *Rickettsia* were detected in 1% of cases (Hercik *et al*., 2017). A study in Bangladesh found ²¹⁵*Salmonella enterica* serovar Typhi (15%), dengue (10%), *Rickettsia*, spp. *Escherichia coli*, 216 *Pseudomonas* spp*., Leptospira* spp*.*, *Coxiella* spp*.*, *Histoplasma*, and *Toxoplasma*; malaria RDT-²¹⁷positive patients were excluded from this study (Ferdousi *et al*., 2023). Much as *S. pneumonia* is 218 not described as a cause of AFI, it causes high morbidity and mortality especially in children 219 under the age of five *(Zar et al.*, 2013)

221 In this study several pathogens of outbreak potential and concern to the Uganda public health
222 were identified as mentioned above. However, the detection of high consequence pathogens were identified as mentioned above. However, the detection of high consequence pathogens 223 rarely reported in Uganda such as West Nile virus, *Bartonella*, and *Coxiella* was not made. To 224 assure that the assay would have detected a variety of low frequency but high impact pathogens, 225 this study included six RVFV and CCHFV samples (RVFv, $n = 5$ and CCHFv, $n = 1$) with a 226 range of Ct values (25-28). All six of these samples were detected as positive for their respective
227 pathogens by TAC with Ct values (26-29). This shows that the performance of TAC is pathogens by TAC with Ct values (26-29). This shows that the performance of TAC is 228 comparable to simplex PCR.

229

²³⁰This study found *Plasmodium* infections to be the most prevalent, similar to findings from a 231 study in Kilombero, Tanzania (Hercik *et al.*, 2017) where 47% of patients recruited into the 232 study became positive for *Plasmodium*. A study on metagenomic next-generation sequencing of ²³³samples from pediatric febrile illness in Tororo, Uganda found the most prevalent AFI etiology 234 to be *Plasmodium falciparum* at 51.1% (Ramesh *et al.*, 2019). As much as *P.vivax* targets were 235 on the card, 15/49 samples that tested positive for plasmodium still remain unspeciated. The 236 rarity and low prevalence of *P. vivax* in sub-Saharan Africa might owe to the fact that there is a 237 wide range of Duffy negative alleles in the population making them more resistant to *P. vivax* 238 (Dhorda *et al.*, 2011) (Howes *et al.*, 2011). These samples may be positive for *P.malaria* or
239 *P.ovale* which have been documented to exist in Uganda (Asua *et al.*, 2017). There was no ²³⁹*P.ovale* which have been documented to exist in Uganda (Asua *et al*., 2017). There was no 240 statistical significance at 95% confidence that any of the clinical characteristics presented were 241 associated to plasmodium infection besides cough. Similarly, complicated Malaria has been 242 associated with lung damage, altered pulmonary functions such as Acute respiratory distress with 243 signs such as cough (Cabezón & Hernández-mora, 2016). In this study, all mortalities are 244 associated with an infection which could be associated to delays in diagnosis or misdiagnosis 245 culminating to inadequate patient support.

246 Some of the limitations of the TAC assay include the need to test 8 samples to avoid waste. In 247 situations where the sample volumes are low plus the necessity to adhere to set turnaround times, 248 the assay becomes expensive. This is because testing less than 6 samples becomes a waste of 249 resources. On the other hand, circumstances of very high sample volumes, testing 6-8 samples ²⁵⁰may be a limitation to meeting the turnaround time. The products from the PCR cannot be used 251 for any downstream analysis like sequencing. In addition, during development, a single 252 annealing temperature is needed therefore the need for optimization of individual assays for 253 efficiency (Heaney *et al.*, 2015).

²⁵⁴**Recommandations**

²⁵⁵From this study, it is eminent to include the TAC card testing as routine for all VHF negative 256 testing done in country. The unspeciated plasmodium positive samples need to be tested for other ²⁵⁷*Plasmodium* species such as *P.malariae* and *P.ovale*. Based on the commonly circulating AFI 258 pathogens in Uganda, , the AFI card needs further be customization to include etiologies such

259 as; COVID-19, monkey pox virus, and measles with clear guidance from the Ministry of Health.

²⁶⁰In addition, a TAC assay targeting travelers can be designed for pathogens that are not endemic

261 to Uganda like *Lassa fever virus*, and *Nipah virus* disease that could otherwise be imported by

262 international travelers from countries where these etiologies are known to exist. While the

- 263 strategy of duplication of pathogen targets reduces the number of pathogens being detected thus
264 making the assay even more expensive, it could increase the efficiency of the assay.
- making the assay even more expensive, it could increase the efficiency of the assay.
-

²⁶⁶**Conclusion**

267 Although the TAC cards are expensive, costing between 350 to 500 USD per card, for the number of pathogens tested and the number of samples that can be tested per card, strategic use 268 number of pathogens tested and the number of samples that can be tested per card, strategic use
269 of the cards could be a cost-effective way to perform passive surveillance for a range of 269 of the cards could be a cost-effective way to perform passive surveillance for a range of pathogens that are of public health importance to Uganda. The TAC system provides flexibility 270 pathogens that are of public health importance to Uganda. The TAC system provides flexibility
271 of testing for multiple pathogen targets within a short period of time and without the need to 271 of testing for multiple pathogen targets within a short period of time and without the need to
272 purchase and maintain multiple kits, positive controls and reference material. Coupled with 272 purchase and maintain multiple kits, positive controls and reference material. Coupled with
273 confirmatory testing at the appropriate reference laboratory for presumptive-positive samples 273 confirmatory testing at the appropriate reference laboratory for presumptive-positive samples
274 identified using TAC, the system could be effective at more quickly recognizing and responding 274 identified using TAC, the system could be effective at more quickly recognizing and responding
275 to outbreaks. Compared to singlex procedures. This study has therefore proved that the AFI-275 to outbreaks. Compared to singlex procedures. This study has therefore proved that the AFI-
276 TAC testing modality is of great value and can be adopted to Uganda for AFI surveillance and 276 TAC testing modality is of great value and can be adopted to Uganda for AFI surveillance and
277 outbreak investigations. outbreak investigations.

²⁷⁸**Conflict of interest statement**

279 The authors declare no conflict of interest exists.

²⁸⁰**Funding source**

- 281 This study was funded by the Uganda Virus Research Institute, the Viral Hemorrhagic Fevers
- 282 program with support from the Centers for Disease Control and prevention

²⁸³**Ethical approval**

284 The study was approved by the office of the Director General of Health services in the Ministry 285 of Health Uganda.

²⁸⁶**Acknowledgements**

287 I acknowledge the centers for Disease control and prevention (CDC) who funded this work
288 through the Viral Hemorrhagic Fevers surveillance program at the Uganda Virus Research ²⁸⁸through the Viral Hemorrhagic Fevers surveillance program at the Uganda Virus Research 289 Institute.

²⁹⁰**REFERENCES**

- 291 Agaba, B. B., Travis, J., Smith, D., Rugera, S. P., Zalwango, M. G., Opigo, J., Katureebe, C.,
- ²⁹²Mpirirwe, R., Bakary, D., Antonio, M., Khalid, B., Ngonzi, J., Kamya, M. R., Kaleebu, P.,
- 293 Piot, P., & Cheng, Q. (2024). Emerging threat of artemisinin partial resistance markers
- 294 (pfk13 mutations) in Plasmodium falciparum parasite populations in multiple geographical
295 locations in high transmission regions of Uganda. *Malaria Journal*, 23(1), 330.
- locations in high transmission regions of Uganda. *Malaria Journal*, 23(1), 330.

²⁹⁶https://doi.org/10.1186/s12936-024-05158-9

- 297 Asua, V., Tukwasibwe, S., Conrad, M., Walakira, A., Nankabirwa, J. I., Mugenyi, L., Kamya,
- 298 M. R., Nsobya, S. L., & Rosenthal, P. J. (2017). Plasmodium species infecting children
- ²⁹⁹presenting with malaria in Uganda. *American Journal of Tropical Medicine and Hygiene*,
- ³⁰⁰*97*(3), 753–757. https://doi.org/10.4269/ajtmh.17-0345
- 301 Balinandi, S., Mulei, S., Whitmer, S., Nyakarahuka, L., Cossaboom, C. M., Shedroff, E.,
- ³⁰²Morales-Betoulle, M., Krapiunaya, I., Tumusiime, A., Kyondo, J., Baluku, J., Namanya, D.,
- 303 Torach, C. R., Mutesi, J., Kiconco, J., Pimundu, G., Muyigi, T., Rowland, J., Nsawotebba,
- ³⁰⁴A., … Klena, J. D. (2024). Crimean-Congo hemorrhagic fever cases diagnosed during an
- 305 outbreak of Sudan virus disease in Uganda, 2022-23. *PLoS Neglected Tropical Diseases*,
- ³⁰⁶*18*(10), e0012595. https://doi.org/10.1371/journal.pntd.0012595

- ³³³Kharod, G., Person, M., Folkema, A., Galloway, R., Elrod, M., Perniciaro, J., Nicholson, W.,
- 334 Patel, N., Bwogi, J., Bukenya, H., Drakeley, C., Mbulaiteye, S., Blaney, D., & Shadomy, S.

- ³³⁵(2016). Uganda National Acute Febrile Illness Agent Detection Serosurvey 2004-2005.
- ³³⁶*International Journal of Infectious Diseases*, *45*, 180.
- ³³⁷https://doi.org/10.1016/j.ijid.2016.02.422
- 338 Kodani, M., Yang, G., Conklin, L. M., Travis, T. C., Whitney, C. G., Anderson, L. J., Schrag, S.
- 339 J., Taylor, T. H., Beall, B. W., Breiman, R. F., Feikin, D. R., Njenga, M. K., Mayer, L. W.,
- 340 Oberste, M. S., Tondella, M. L. C., Winchell, J. M., Lindstrom, S. L., Erdman, D. D., &
- ³⁴¹Fields, B. S. (2011). *Application of TaqMan Low-Density Arrays for Simultaneous*
- *Detection of Multiple Respiratory Pathogens* □. 49(6), 2175–2182.
343 https://doi.org/10.1128/JCM.02270-10
- https://doi.org/10.1128/JCM.02270-10
- ³⁴⁴Lesho, E., Clifford, R., Onmus-Leone, F., Appalla, L., Snesrud, E., Kwak, Y., Ong, A.,
- ³⁴⁵Maybank, R., Waterman, P., Rohrbeck, P., Julius, M., Roth, A., Martinez, J., Nielsen, L.,
- 346 Steele, E., McGann, P., & Hinkle, M. (2016). The challenges of implementing next
- ³⁴⁷generation sequencing across a large healthcare system, and the molecular epidemiology
- ³⁴⁸and antibiotic susceptibilities of carbapenemase-producing bacteria in the healthcare system
- 349 of the U.S. Department of Defense. *PLoS ONE*, 11(5), 1–12.
- ³⁵⁰https://doi.org/10.1371/journal.pone.0155770
- 351 Liu, J., Ochieng, C., Wiersma, S., Ströher, U., Towner, J. S., Whitmer, S., Nichol, S. T., Moore,
- 352 C. C., Kersh, G. J., Kato, C., Sexton, C., Petersen, J., Massung, R., Hercik, C., Crump, J. A.,
- ³⁵³Kibiki, G., Maro, A., Mujaga, B., Gratz, J., … Houpt, E. (2016). *Development of a TaqMan*
- ³⁵⁴*Array Card for Acute-Febrile-Illness Outbreak Investigation and Surveillance of Emerging*
- ³⁵⁵*Pathogens , Including Ebola Virus*. *54*(1), 49–58. https://doi.org/10.1128/JCM.02257-
- 356 15.Editor
- 357 Mambula, G., Nanjebe, D., Munene, A., Guindo, O., Salifou, A., Mamaty, A. A., Rattigan, S.,
- ³⁵⁸Ellis, S., Khavessian, N., van der Pluijm, R. W., Marquer, C., Adehossi, I. A., &
- ³⁵⁹Langendorf, C. (2023). Practices and challenges related to antibiotic use in paediatric
- 360 treatment in hospitals and health centres in Niger and Uganda: a mixed methods study.
- ³⁶¹*Antimicrobial Resistance and Infection Control*, *12*(1), 1–12.
- ³⁶²https://doi.org/10.1186/s13756-023-01271-7
- 363 Maze, M. J., Bassat, Q., Feasey, N. A., Mandomando, I., Musicha, P., & Crump, J. A. (2018).

- management. *Clinical Microbiology and Infection*, 24(8), 808–814.
- ³⁶⁶https://doi.org/10.1016/j.cmi.2018.02.011
- 367 Racsa, L. D., Kraft, C. S., Olinger, G. G., & Hensley, L. E. (2016). Viral Hemorrhagic Fever ³⁶⁸Diagnostics. *Clinical Infectious Diseases*, *62*(2), 214–219.
- 369 https://doi.org/10.1093/cid/civ792
- 370 Ramesh, A., Nakielny, S., Hsu, J., Kyohere, M., Byaruhanga, O., Bourcy, C. De, Egger, R.,
- 371 Dimitrov, B., Juan, F., Sheu, J., Wang, J., Kalantar, K., Langelier, C., Ruel, T., Mpimbaza,
- ³⁷²A., Wilson, M. R., Rosenthal, P. J., & Id, L. D. (2019). *Metagenomic next-generation*

³⁷³*sequencing of samples from pediatric febrile illness in*. *Lmic*, 1–17.

- ³⁷⁴Rose, H. L., Rachwal, P. A., Murch, A. L., Weller, S. A., Lukaszewski, R. A., & Cox, V. (2012).
- 375 The Potential of TaqMan Array Cards for Detection of Multiple Biological Agents by Real-376 Time PCR. *PLoS ONE*, 7(4), e35971. https://doi.org/10.1371/journal.pone.0035971
- 377 Shoemaker, T., Balinandi, S., Tumusiime, A., Wamala, J., Knust, B., Schafer, I., Campbell, S.,
- 378 Cannon, D., Erickson, B. R., Gibbons, A., Nayakarahuka, L., Lutwama, J., Mbidde, E.,
- 379 Ströher, U., Rollin, P., & Nichol, S. (2013). Establishment and successes of the uganda
- 380 national viral hemorrhagic fever surveillance program and high-containment laboratory,
- ³⁸¹2010-2013. *American Journal of Tropical Medicine and Hygiene*.
- ³⁸²Wamala, J. F., Malimbo, M., Okot, C. L., Atai-Omoruto, A. D., Tenywa, E., Miller, J. R.,
- 383 Balinandi, S., Shoemaker, T., Oyoo, C., Omony, E. O., Kagirita, A., Musenero, M. M.,
- 384 Makumbi, I., Nanyunja, M., Lutwama, J. J., Downing, R., & Mbonye, A. K. (2012).
- ³⁸⁵Epidemiological and laboratory characterization of a yellow fever outbreak in northern
- ³⁸⁶Uganda, October 2010-January 2011. *International Journal of Infectious Diseases*.
- ³⁸⁷https://doi.org/10.1016/j.ijid.2012.03.004
- ³⁸⁸Zar, H. J., Madhi, S. A., Aston, S. J., & Gordon, S. B. (2013). Pneumonia in low and middle
- 389 income countries: Progress and challenges. *Thorax*, $68(11)$, 1052–1056.
- ³⁹⁰https://doi.org/10.1136/thoraxjnl-2013-204247
- 391 Agaba, B. B., Travis, J., Smith, D., Rugera, S. P., Zalwango, M. G., Opigo, J., Katureebe, C.,

³⁶⁴ The epidemiology of febrile illness in sub-Saharan Africa \Box : implications for diagnosis and management. *Clinical Microbiology and Infection*, 24(8), 808–814.

⁴²⁰*Short Review*. *1*(1), 1–6. https://doi.org/10.30699/mmlj17-01-01

- 421 Heaney, J., Rolfe, K., Gleadall, N. S., Greatorex, J. S., & Curran, M. D. (2015). Low-density
- ⁴²²TaqMan® array cards for the detection of pathogens. In *Methods in Microbiology* (1st ed.,
- ⁴²³Vol. 42). Elsevier Ltd. https://doi.org/10.1016/bs.mim.2015.06.002
- 424 Hercik, C., Cosmas, L., Mogeni, O. D., Wamola, N., Kohi, W., Omballa, V., Ochieng, M.,
- 425 Lidechi, S., Bonventure, J., Ochieng, C., Onyango, C., Fields, B. S., Mfinanga, S., &
- 426 Montgomery, J. M. (2017). A diagnostic and epidemiologic investigation of acute febrile
- ⁴²⁷illness (AFI) in Kilombero, Tanzania. *PLoS ONE*, *12*(12), 5–14.
- ⁴²⁸https://doi.org/10.1371/journal.pone.0189712
- 429 Howes, R. E., Patil, A. P., Piel, F. B., Nyangiri, O. A., Kabaria, C. W., Gething, P. W.,
430 Zimmerman, P. A., Barnadas, C., Beall, C. M., Gebremedhin, A., Ménard, D., Wil
- Zimmerman, P. A., Barnadas, C., Beall, C. M., Gebremedhin, A., Ménard, D., Williams, T.
- 431 N., Weatherall, D. J., & Hay, S. I. (2011). The global distribution of the Duffy blood group.
- ⁴³²*Nature Communications*, *2*(1). https://doi.org/10.1038/ncomms1265
- ⁴³³Kharod, G., Person, M., Folkema, A., Galloway, R., Elrod, M., Perniciaro, J., Nicholson, W.,
- 434 Patel, N., Bwogi, J., Bukenya, H., Drakeley, C., Mbulaiteye, S., Blaney, D., & Shadomy, S.
- ⁴³⁵(2016). Uganda National Acute Febrile Illness Agent Detection Serosurvey 2004-2005.
- ⁴³⁶*International Journal of Infectious Diseases*, *45*, 180.
- ⁴³⁷https://doi.org/10.1016/j.ijid.2016.02.422
- 438 Kodani, M., Yang, G., Conklin, L. M., Travis, T. C., Whitney, C. G., Anderson, L. J., Schrag, S.
- 439 J., Taylor, T. H., Beall, B. W., Breiman, R. F., Feikin, D. R., Njenga, M. K., Mayer, L. W.,
- 440 Oberste, M. S., Tondella, M. L. C., Winchell, J. M., Lindstrom, S. L., Erdman, D. D., &
- ⁴⁴¹Fields, B. S. (2011). *Application of TaqMan Low-Density Arrays for Simultaneous*
- ⁴⁴²*Detection of Multiple Respiratory Pathogens* . *49*(6), 2175–2182.
- ⁴⁴³https://doi.org/10.1128/JCM.02270-10
- ⁴⁴⁴Lesho, E., Clifford, R., Onmus-Leone, F., Appalla, L., Snesrud, E., Kwak, Y., Ong, A.,
- ⁴⁴⁵Maybank, R., Waterman, P., Rohrbeck, P., Julius, M., Roth, A., Martinez, J., Nielsen, L.,
- 446 Steele, E., McGann, P., & Hinkle, M. (2016). The challenges of implementing next
- ⁴⁴⁷generation sequencing across a large healthcare system, and the molecular epidemiology
- ⁴⁴⁸and antibiotic susceptibilities of carbapenemase-producing bacteria in the healthcare system

449 of the U.S. Department of Defense. *PLoS ONE*, 11(5), 1–12.

- ⁴⁵⁰https://doi.org/10.1371/journal.pone.0155770
- ⁴⁵¹Liu, J., Ochieng, C., Wiersma, S., Ströher, U., Towner, J. S., Whitmer, S., Nichol, S. T., Moore,
- 452 C. C., Kersh, G. J., Kato, C., Sexton, C., Petersen, J., Massung, R., Hercik, C., Crump, J. A.,
- ⁴⁵³Kibiki, G., Maro, A., Mujaga, B., Gratz, J., … Houpt, E. (2016). *Development of a TaqMan*
- ⁴⁵⁴*Array Card for Acute-Febrile-Illness Outbreak Investigation and Surveillance of Emerging*
- ⁴⁵⁵*Pathogens , Including Ebola Virus*. *54*(1), 49–58. https://doi.org/10.1128/JCM.02257-
- 456 15.Editor
- 457 Mambula, G., Nanjebe, D., Munene, A., Guindo, O., Salifou, A., Mamaty, A. A., Rattigan, S.,
- 458 Ellis, S., Khavessian, N., van der Pluijm, R. W., Marquer, C., Adehossi, I. A., &
- ⁴⁵⁹Langendorf, C. (2023). Practices and challenges related to antibiotic use in paediatric
- 460 treatment in hospitals and health centres in Niger and Uganda: a mixed methods study.
- ⁴⁶¹*Antimicrobial Resistance and Infection Control*, *12*(1), 1–12.
- ⁴⁶²https://doi.org/10.1186/s13756-023-01271-7
- 463 Maze, M. J., Bassat, Q., Feasey, N. A., Mandomando, I., Musicha, P., & Crump, J. A. (2018).
- 464 The epidemiology of febrile illness in sub-Saharan Africa \Box : implications for diagnosis and
465 management. *Clinical Microbiology and Infection*, 24(8), 808–814.
- ⁴⁶⁵management. *Clinical Microbiology and Infection*, *24*(8), 808–814.
- ⁴⁶⁶https://doi.org/10.1016/j.cmi.2018.02.011
- 467 Racsa, L. D., Kraft, C. S., Olinger, G. G., & Hensley, L. E. (2016). Viral Hemorrhagic Fever ⁴⁶⁸Diagnostics. *Clinical Infectious Diseases*, *62*(2), 214–219.
- 469 https://doi.org/10.1093/cid/civ792
- 470 Ramesh, A., Nakielny, S., Hsu, J., Kyohere, M., Byaruhanga, O., Bourcy, C. De, Egger, R.,
- 471 Dimitrov, B., Juan, F., Sheu, J., Wang, J., Kalantar, K., Langelier, C., Ruel, T., Mpimbaza,
- ⁴⁷²A., Wilson, M. R., Rosenthal, P. J., & Id, L. D. (2019). *Metagenomic next-generation*
- ⁴⁷³*sequencing of samples from pediatric febrile illness in*. *Lmic*, 1–17.
- 474 Rose, H. L., Rachwal, P. A., Murch, A. L., Weller, S. A., Lukaszewski, R. A., & Cox, V. (2012).
- 475 The Potential of TaqMan Array Cards for Detection of Multiple Biological Agents by Real-
- ⁴⁷⁶Time PCR. *PLoS ONE*, *7*(4), e35971. https://doi.org/10.1371/journal.pone.0035971

- 477 Shoemaker, T., Balinandi, S., Tumusiime, A., Wamala, J., Knust, B., Schafer, I., Campbell, S.,
- 478 Cannon, D., Erickson, B. R., Gibbons, A., Nayakarahuka, L., Lutwama, J., Mbidde, E.,
- 479 Ströher, U., Rollin, P., & Nichol, S. (2013). Establishment and successes of the uganda
- 480 national viral hemorrhagic fever surveillance program and high-containment laboratory,
- ⁴⁸¹2010-2013. *American Journal of Tropical Medicine and Hygiene*.
- ⁴⁸²Wamala, J. F., Malimbo, M., Okot, C. L., Atai-Omoruto, A. D., Tenywa, E., Miller, J. R.,
- 483 Balinandi, S., Shoemaker, T., Oyoo, C., Omony, E. O., Kagirita, A., Musenero, M. M.,
- 484 Makumbi, I., Nanyunja, M., Lutwama, J. J., Downing, R., & Mbonye, A. K. (2012).
- ⁴⁸⁵Epidemiological and laboratory characterization of a yellow fever outbreak in northern
- ⁴⁸⁶Uganda, October 2010-January 2011. *International Journal of Infectious Diseases*.
- ⁴⁸⁷https://doi.org/10.1016/j.ijid.2012.03.004
- 488 Zar, H. J., Madhi, S. A., Aston, S. J., & Gordon, S. B. (2013). Pneumonia in low and middle
- ⁴⁸⁹income countries: Progress and challenges. *Thorax*, *68*(11), 1052–1056.
- ⁴⁹⁰https://doi.org/10.1136/thoraxjnl-2013-204247

491